Transcutaneous port for levodopa/carbidopa intestinal gel administration in Parkinson's disease

Acta Neurologica Scandinavica

Volumn 133, Issue 3, 2016, Pages 208-215

  van Laar, T ^a   Nyholm, D ^b   Nyman, R ^b  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b UPPSALA UNIVERSITY   (Sweden)

Author keywords

Clinical trial; Levodopa carbidopa infusion; Parkinson's disease; Percutaneous endoscopic gastrojejunostomy; Transcutaneous port

Indexed keywords

CARBIDOPA PLUS LEVODOPA; ANTIPARKINSON AGENT; CARBIDOPA; GEL; LEVODOPA;

ADULT; AGED; ARTICLE; CATHETER; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DEVICE FAILURE; DRUG DELIVERY DEVICE; ENDOSCOPIC SURGERY; FEMALE; GASTROJEJUNOSTOMY; GEL; HUMAN; INFECTION; INFLAMMATION; MALE; PARKINSON DISEASE; PATIENT SAFETY; POSTOPERATIVE COMPLICATION; STOMA; ADVERSE EFFECTS; CUTANEOUS DRUG ADMINISTRATION; FOLLOW UP; GASTRIC BYPASS SURGERY; GASTROSCOPY; INTESTINE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; PROSPECTIVE STUDY; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME; VASCULAR ACCESS DEVICE;

ADMINISTRATION, CUTANEOUS; ADULT; AGED; ANTIPARKINSON AGENTS; CARBIDOPA; EQUIPMENT FAILURE; FEMALE; FOLLOW-UP STUDIES; GASTRIC BYPASS; GASTROSCOPY; GELS; HUMANS; INTESTINES; LEVODOPA; MALE; MIDDLE AGED; PARKINSON DISEASE; PATIENT SAFETY; POSTOPERATIVE COMPLICATIONS; PROSPECTIVE STUDIES; TREATMENT OUTCOME; VASCULAR ACCESS DEVICES;

EID: 84956740273     PISSN: 00016314     EISSN: 16000404     Source Type: Journal    
DOI: 10.1111/ane.12464     Document Type: Article

References (20)

1. Marsden CD. Problems with long-term levodopa therapy for Parkinson's disease. Clin Neuropharmacol 1994;17:32-44.
2. Bredberg E, Nilsson D, Johansson K et al. Intraduodenal infusion of a water-based levodopa dispersion for optimisation of the therapeutic effect in severe Parkinson's disease. Eur J Clin Pharmacol 1993;45:117-22.
3. Nyholm D, Askmark H, Gomes-Trolin C et al. Optimizing levodopa pharmacokinetics: intestinal infusion versus oral sustained-release tablets. Clin Neuropharmacol 2003;26:156-63.
4. Nilsson D, Nyholm D, Aquilonius SM. Duodenal levodopa infusion in Parkinson's disease-long-term experience. Acta Neurol Scand 2001;104:343-8.
5. Nyholm D, Nilsson Remahl AI, Dizdar N et al. Duodenal levodopa infusion monotherapyvs oral polypharmacy in advanced Parkinson disease. Neurology 2005;64:216-23.
6. Nyholm D. Enteral levodopa/carbidopa gel infusion for the treatment of motor fluctuations and dyskinesias in advanced Parkinson's disease. Expert Rev Neurother 2006;6:1403-11.
7. Olanow CW, Kieburtz K, Odin P et al. Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study. Lancet Neurol 2014;13:141-9.
8. Devos D. Patient profile, indications, efficacy and safety of duodenal Levodopa infusion in advanced Parkinson's disease. Mov Disord 2009;24:993-1000.
9. Fernandez HH, Standaert DG, Hauser RA et al. Levodopa-carbidopa intestinal gel in advanced Parkinson's disease: final 12-month, open-label results. Mov Disord 2015;30:500-9.
10. Karlsborg M, Korbo L, Regeur L et al. Duodopa pump treatment in patients with advanced Parkinson's disease. Dan Med Bull 2010;57:A4155.
11. Nyholm D, Lewander T, Johansson A et al. Enteral levodopa/carbidopa infusion in advanced Parkinson disease: long-term exposure. Clin Neuropharmacol 2008;31:63-73.
12. Lundgren D, Axelsson R. Soft-tissue-anchored percutaneous device for long-term intracorporeal access. J Invest Surg 1989;2:17-27.
13. Nyman R, Eklöf H, Eriksson LG et al. Soft-tissue-anchored transcutaneous port for long-term percutaneous transhepatic biliary drainage. Cardiovasc Intervent Radiol 2005;28:53-9.
14. Meppelink AM, Nyman R, van Laar T et al. Transcutaneous port for continuous duodenal levodopa/carbidopa administration in Parkinson's disease. Mov Disord 2011;26:331-4.
15. Nyman R, Lundgren D, Nyholm D. Soft tissue-anchored transcutaneous port attached to an intestinal tube for long-term gastroduodenal infusion of levodopa/carbidopa in Parkinson disease. J Vasc Interv Radiol 2009;20:500-5.
16. Dun CA, Faber HT, de Wolf MJ et al. Assessment of more than 1, 000 implanted percutaneous bone conduction devices: skin reactions and implant survival. Otol Neurotol 2012;33:192-8.
17. Holgers KM, Tjellström A, Bjursten LM et al. Soft tissue reactions around percutaneous implants: a clinical study of soft tissue conditions around skin-penetrating titanium implants for bone-anchored hearing aids. Am J Otol 1988;9:56-9.
18. Holgers KM, Bjursten LM, Thomsen P et al. Experience with percutaneous titanium implants in the head and neck: a clinical and histological study. J Invest Surg 1989;2:7-16.
19. Holgers KM, Ljungh A. Cell surface characteristics of microbiological isolates from human percutaneous titanium implants in the head and neck. Biomaterials 1999;20:1319-26.
20. Tjellstrom A, Granstrom G. One-stage procedure to establish osseointegration: a zero to five years follow-up report. J Laryngol Otol 1995;109:593-8.